Crossmark

Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells

Crossref DOI link: https://doi.org/10.1007/s00262-025-04081-5

Published Online: 2025-05-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bopp, Anna R.

Lamenza, Felipe F.

Upadhaya, Puja

Ryan, Nathan M.

Kazmierowicz, Natalie

Jordanides, Pete P.

Siddiqui, Arham

Pracha, Sherefuddin H.

Roth, Peyton

Iwenofu, O. Hans

Oghumu, Steve
Funding

Funding for this research was provided by:

National Institutes of Health (DP1DA054344)

American Cancer Society (RSG-19079-01-TBG)
License Information

Text and Data Mining valid from 2025-05-30

Version of Record valid from 2025-05-30
More Information

Article History

Received: 10 March 2025

Accepted: 6 May 2025

First Online: 30 May 2025

Declaration

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below